KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) R&D In Process (2021 - 2025)

Vertex Pharmaceuticals has reported R&D In Process over the past 5 years, most recently at $56.5 million for Q4 2025.

  • Quarterly results put R&D In Process at $56.5 million for Q4 2025, down 35.43% from a year ago — trailing twelve months through Dec 2025 was $133.0 million (down 97.1% YoY), and the annual figure for FY2025 was $133.0 million, down 97.13%.
  • R&D In Process for Q4 2025 was $56.5 million at Vertex Pharmaceuticals, up from $54.5 million in the prior quarter.
  • Over the last five years, R&D In Process for VRTX hit a ceiling of $4.4 billion in Q2 2024 and a floor of $2.0 million in Q1 2022.
  • Median R&D In Process over the past 5 years was $54.5 million (2025), compared with a mean of $325.1 million.
  • Biggest five-year swings in R&D In Process: soared 3881.9% in 2024 and later crashed 99.95% in 2025.
  • Vertex Pharmaceuticals' R&D In Process stood at $113.2 million in 2021, then tumbled by 80.04% to $22.6 million in 2022, then fell by 21.24% to $17.8 million in 2023, then surged by 391.57% to $87.5 million in 2024, then plummeted by 35.43% to $56.5 million in 2025.
  • The last three reported values for R&D In Process were $56.5 million (Q4 2025), $54.5 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.